CY1111874T1 - Ενεσιμη χορηγηση αριπιπραζολης - Google Patents

Ενεσιμη χορηγηση αριπιπραζολης

Info

Publication number
CY1111874T1
CY1111874T1 CY20111100940T CY111100940T CY1111874T1 CY 1111874 T1 CY1111874 T1 CY 1111874T1 CY 20111100940 T CY20111100940 T CY 20111100940T CY 111100940 T CY111100940 T CY 111100940T CY 1111874 T1 CY1111874 T1 CY 1111874T1
Authority
CY
Cyprus
Prior art keywords
extended release
aripiprazol
administrative administration
injection
aripiprazole
Prior art date
Application number
CY20111100940T
Other languages
English (en)
Inventor
Josiah Brown
Original Assignee
Alkermes, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34116189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111874(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes, Inc. filed Critical Alkermes, Inc.
Publication of CY1111874T1 publication Critical patent/CY1111874T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Abstract

Η παρούσα εφεύρεση σχετίζεται, εν μέρει, με την ανακάλυψη ότι φαρμακευτική σύνθεση που περιλαμβάνει αριπιπραζόλη και φορέα, που χορηγήθηκε με ένεση βλωμού (bolus), είχε ως αποτέλεσμα προφίλ εκτεταμένης απελευθέρωσης, παρόμοιο με αυτό που επιτεύχθηκε με την ένεση σκευάσματος μικροσφαιριδίων πολύ λακτιδιο-συν-γλυκολιδίου, που περιείχαν τη δραστική ουσία. Αυτό το αναπάντεχο αποτέλεσμα υποδεικνύει ότι μπορούν να επιτευχθούν φαρμακολογικά επωφελή εκτεταμένης απελευθέρωσης σκευάσματα, χωρίς την πολυπλοκότητα και τα ακριβά κόστη, που σχετίζονται με την παρασκευή μικροσφαιριδίων.
CY20111100940T 2003-08-06 2011-09-29 Ενεσιμη χορηγηση αριπιπραζολης CY1111874T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/635,221 US20050032811A1 (en) 2003-08-06 2003-08-06 Methods for administering aripiprazole
EP04779411A EP1660037B1 (en) 2003-08-06 2004-07-29 Aripiprazole injectable suspension

Publications (1)

Publication Number Publication Date
CY1111874T1 true CY1111874T1 (el) 2015-11-04

Family

ID=34116189

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100940T CY1111874T1 (el) 2003-08-06 2011-09-29 Ενεσιμη χορηγηση αριπιπραζολης

Country Status (22)

Country Link
US (9) US20050032811A1 (el)
EP (2) EP2340810A1 (el)
JP (3) JP5300194B2 (el)
CN (2) CN1845721A (el)
AT (1) ATE522200T1 (el)
AU (1) AU2004264886C1 (el)
CA (1) CA2534997C (el)
CY (1) CY1111874T1 (el)
DK (1) DK1660037T3 (el)
ES (1) ES2369893T3 (el)
HK (1) HK1091725A1 (el)
HR (1) HRP20110646T1 (el)
IL (1) IL173441A (el)
MX (1) MXPA06001350A (el)
NO (1) NO339816B1 (el)
NZ (1) NZ545037A (el)
PL (1) PL1660037T3 (el)
PT (1) PT1660037E (el)
SE (1) SE1660037T5 (el)
SI (1) SI1660037T1 (el)
WO (1) WO2005016262A2 (el)
ZA (1) ZA200601385B (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
DE602004017342D1 (de) * 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
EP3058972A1 (en) * 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
KR101892745B1 (ko) * 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
NZ582415A (en) * 2007-07-31 2012-05-25 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
JP5732453B2 (ja) * 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ
DK2445502T4 (da) * 2009-06-25 2022-11-28 Alkermes Pharma Ireland Ltd Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR101936968B1 (ko) 2010-10-18 2019-01-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 주사용 서방형 제제
AR083884A1 (es) * 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
RU2757859C2 (ru) 2011-03-18 2021-10-21 Алкермес Фарма Айэленд Лимитед Фармацевтические композиции, содержащие водонерастворимое антипсихотическое средство и сложные эфиры сорбитана
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
CN103301461B (zh) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 一种长效注射制剂及其制备方法和用途
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN105078898B (zh) * 2014-05-22 2018-08-28 上海现代药物制剂工程研究中心有限公司 阿立哌唑长效缓释微粒注射剂及其制备方法
MX371417B (es) * 2014-08-18 2020-01-29 Alkermes Pharma Ireland Ltd Composiciones de profarmacos de aripiprazol.
LT3185867T (lt) 2014-08-25 2021-06-10 Alkermes Pharma Ireland Limited Apiprazolo darinių kristalizavimo procesas prailginto atpalaidavimo vaisto formose, skirtose šizofrenijos gydymui
CN106474058B (zh) 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
WO2019173230A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) * 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230310417A1 (en) 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
WO2021201239A1 (en) 2020-04-01 2021-10-07 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
CN115212174B (zh) * 2022-07-18 2024-02-20 辉粒药业(苏州)有限公司 一种载阿立哌唑长效缓释微球及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5832899A (ja) * 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US7179486B1 (en) * 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002026726A2 (en) * 2000-09-26 2002-04-04 The Johns Hopkins University Antiviral compositions and methods of use
DE10048868A1 (de) * 2000-10-02 2002-04-11 Basf Ag Verfahren und Vorrichtung zur Einmischung von Zusatzstoffen während der Konditionierung von Tierfutter
JP2002191256A (ja) 2000-12-26 2002-07-09 Yoshikatsu Nakajima 水 槽
US6884768B2 (en) * 2001-06-14 2005-04-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
DE602004017342D1 (de) * 2003-10-23 2008-12-04 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren

Also Published As

Publication number Publication date
US8338428B2 (en) 2012-12-25
AU2004264886B2 (en) 2007-06-07
ATE522200T1 (de) 2011-09-15
CN1845721A (zh) 2006-10-11
HK1091725A1 (en) 2007-01-26
DK1660037T3 (da) 2011-12-12
EP2340810A1 (en) 2011-07-06
US20180169005A1 (en) 2018-06-21
JP2014001250A (ja) 2014-01-09
US8759351B2 (en) 2014-06-24
US20210346282A1 (en) 2021-11-11
NO339816B1 (no) 2017-02-06
IL173441A (en) 2013-04-30
AU2004264886A1 (en) 2005-02-24
US8338427B2 (en) 2012-12-25
PT1660037E (pt) 2011-10-24
JP2010248258A (ja) 2010-11-04
CN102133171A (zh) 2011-07-27
US20190231679A1 (en) 2019-08-01
US20050032811A1 (en) 2005-02-10
JP5764634B2 (ja) 2015-08-19
NO20060638L (no) 2006-04-26
US20090143403A1 (en) 2009-06-04
NZ545037A (en) 2008-10-31
SI1660037T1 (sl) 2012-05-31
HRP20110646T1 (hr) 2011-12-31
CA2534997A1 (en) 2005-02-24
JP5300194B2 (ja) 2013-09-25
WO2005016262A3 (en) 2005-09-09
US20120289516A1 (en) 2012-11-15
IL173441A0 (en) 2006-06-11
US20140275109A1 (en) 2014-09-18
WO2005016262A2 (en) 2005-02-24
ES2369893T3 (es) 2011-12-07
MXPA06001350A (es) 2006-08-23
ZA200601385B (en) 2007-02-28
EP1660037B1 (en) 2011-08-31
US20130090343A1 (en) 2013-04-11
PL1660037T3 (pl) 2012-03-30
EP1660037A4 (en) 2008-09-24
EP1660037A2 (en) 2006-05-31
SE1660037T5 (el) 2015-09-15
JP5453194B2 (ja) 2014-03-26
AU2004264886C1 (en) 2021-06-03
JP2007501236A (ja) 2007-01-25
CA2534997C (en) 2011-11-01
US20230218506A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
CY1111874T1 (el) Ενεσιμη χορηγηση αριπιπραζολης
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
BR0212475A (pt) Composições farmacêuticas
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
ATE432689T1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
ATE450252T1 (de) Arzneimittel-mikroteilchen
WO2006026592A3 (en) Oral administration of poorly absorbed drugs, methods and compositions related thereto
NZ594618A (en) Transdermal pharmaceutical preparations
WO2010015665A3 (en) Parenteral composition comprising microspheres with a diameter between 10 and 20 microns
BR0318319A (pt) métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
DE60326859D1 (de) Arzneimittelverabreichung
WO2005120542A3 (en) Methods of treating disease with random copolymers
DE60140997D1 (de) Therapeutische zusammensetzungen zur pulmonalen verabreichung
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
BR0013283A (pt) Agente farmacêutico que compreende um derivado de benzamida como ingrediente ativo
BRPI0407438A (pt) Sistema terapêutico compreendendo amoxicilina e ácido clavulânico
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
WO2005030132A3 (en) Therapeutic regimens for administering drug combinations
ATE334658T1 (de) Arzneimittel zur verabreichung an schleimhäute
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
WO2005062874A3 (en) Compounds and compositions for delivering active agents
BR0315231A (pt) Compostos com base em glicose com afinidade para p-seletina